Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBITDA Margin (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EBITDA Margin for 15 consecutive years, with 2.22% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 1167.0% to 2.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.88% through Dec 2025, down 1440.0% year-over-year, with the annual reading at 5.88% for FY2025, 1440.0% down from the prior year.
  • EBITDA Margin hit 2.22% in Q4 2025 for Corcept Therapeutics, down from 4.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 32.09% in Q4 2021 to a low of 2.17% in Q1 2025.
  • Historically, EBITDA Margin has averaged 21.04% across 5 years, with a median of 23.26% in 2023.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 685bps in 2021 and later tumbled -2061bps in 2025.
  • Year by year, EBITDA Margin stood at 32.09% in 2021, then tumbled by -32bps to 21.83% in 2022, then increased by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then plummeted by -84bps to 2.22% in 2025.
  • Business Quant data shows EBITDA Margin for CORT at 2.22% in Q4 2025, 4.92% in Q3 2025, and 13.72% in Q2 2025.